Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old (GRAVITATE)

20. juli 2026 opdateret af: Biogen

A Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Graves' Disease

In this study, researchers will learn more about the use of felzartamab in participants with Graves' Disease, also known as GD. GD is an autoimmune disease, which means the body's immune system attacks its own healthy cells. In people with GD, the immune system produces abnormal antibodies, called thyroid-stimulating hormone receptor antibodies (TRAb), that attack the thyroid gland. This causes the thyroid to become too active and produce too much hormone, a condition called hyperthyroidism.

Participants with GD are often treated with anti-thyroid drugs, or ATDs, which are medicines that help bring thyroid hormone levels back to normal. Felzartamab is designed to target certain immune cells that produce the abnormal TRAb antibodies.

The main goal of the study is to learn whether felzartamab can help bring thyroid hormone levels back to normal and allow participants to stop taking ATDs. Participants will receive either felzartamab or placebo during the study. A placebo looks like the study drug but contains no real medicine.

The main question that researchers want to answer is:

• How many participants have normal thyroid levels without receiving any ATD medicine at Week 24?

Researchers will also learn more about the safety of felzartamab and how the body processes the drug.

The study will be done as follows:

  • Participants will be screened to check if they can join the study.
  • This is a double-blind study, which means neither the participants, study doctor, or site staff will know if participants are receiving felzartamab or a placebo.
  • Participants will be placed into 1 of 3 groups. Two groups will receive felzartamab while the other receives placebo.
  • Participants will receive felzartamab or placebo as intravenous (IV) infusions, which are slow injections into a vein using a needle. The Treatment Period will last 20 weeks.
  • During the Treatment Period, the study doctor may gradually lower the dose of the ATD if a participant's thyroid levels become normal.
  • Afterwards, participants will enter a follow-up period which will last 12 weeks.
  • In total, participants will have 22 study visits. Participants will stay in the study for about 9 months (up to 36 weeks).

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The primary objective of the study is to evaluate the efficacy of felzartamab compared to placebo in participants with Grave's disease (GD). The secondary objectives of the study are to evaluate the safety, efficacy and pharmacokinetics (PK) of felzartamab in participants with GD.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

60

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Key Inclusion Criteria:

  • Have active disease and are thyroid-stimulating hormone receptor antibodies (TRAb) positive, defined as:

    • Free thyroxine (FT4) and free triiodothyronine (FT3), within the reference range,
    • suppressed thyroid-stimulating hormone (TSH)
    • TRAb levels > upper limit of normal (ULN)
  • Participants must be receiving stable dose of anti-thyroid drugs (ATD) for at least 12 weeks prior to randomization.
  • Must agree to refrain from blood product donation from Screening through end of study. If a participant terminates early from the study, they must refrain from blood product donation for 90 days following the last dose of study drug.

Key Exclusion Criteria:

  • History of thyroidectomy or radioactive iodine therapy.
  • ATD dose change within 12 weeks prior to Day1, or anticipated need for dose adjustment prior to randomization (except for protocol-defined safety management).
  • Active, moderate-to-severe, or sight threatening thyroid eye disease (TED) (as assessed by the clinical activity score [CAS]), or requirement for imminent or ongoing TED-directed therapy (e.g., systemic glucocorticoids, biologic therapy, orbital radiation, surgery).
  • Any history of malignancy within 5 years prior to Screening except for adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer.
  • History of hyperthyroidism not caused by GD (e.g. toxic multinodular goiter, autonomous thyroid nodule, acute inflammatory thyroiditis) and/or history or presence of thyroid storm.
  • Type 1 diabetes and type 2 diabetes mellitus with hemoglobin A1c (HbA1c) > 8%.
  • Known or suspected history of hypersensitivity to felzartamab or its excipients.
  • Use of immunosuppressive therapy within 5 half-lives/12 weeks of Screening.
  • Co-existing autoimmune diseases that require systemic immunosuppressants (e.g., cyclosporine, methotrexate, biologics, monoclonals).
  • Prior use of an anti-Neonatal Fragment Crystallizable Receptor (FcRn) therapy or intravenous immunoglobulin (IVIg) within 6 months of the last dose prior to Screening.
  • Any condition that requires chronic use of high-dose steroids.

NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Felzartamab
Deltagerne vil modtage flere IV-doser af felzartamab.
Medicin: Felzartamab
Administreret IV
Andre navne:
  • MOR202
  • MOR03087
  • TJ202
  • BIIB148
Placebo komparator: Placebo
Participants will receive multiple IV doses of placebo.
Medicin: Placebo
Administreret IV
Eksperimentel: Felzartamab or Placebo
Participants will receive multiple IV doses of felzartamab or placebo.
Medicin: Placebo
Administreret IV
Medicin: Felzartamab
Administreret IV
Andre navne:
  • MOR202
  • MOR03087
  • TJ202
  • BIIB148

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Percentage of Participants who are Euthyroid and off Anti-Thyroid Drugs (ATD) at Week 24
Tidsramme: At Week 24
At Week 24

Sekundære resultatmål

Resultatmål
Tidsramme
Percentage of Participants who Have Down-Titrated to ≤ 50% of Their Baseline ATD and are Euthyroid at Week 12 and Week 24
Tidsramme: At Weeks 12 and 24
At Weeks 12 and 24
Percentage of Participants who are Euthyroid at Week 12 and Week 24
Tidsramme: At Weeks 12 and 24
At Weeks 12 and 24
Change From Baseline in Free Triiodothyronine (FT3)
Tidsramme: Baseline up to Week 32
Baseline up to Week 32
Change From Baseline in Free Thyroxine (FT4)
Tidsramme: Baseline up to Week 32
Baseline up to Week 32
Change From Baseline in Thyroid-Stimulating Hormone (TSH)
Tidsramme: Baseline up to Week 32
Baseline up to Week 32
Change From Baseline in ATD Levels
Tidsramme: Up to Week 24
Up to Week 24
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)
Tidsramme: From first dose of study drug up to end of study follow-up (Up to Week 32)
From first dose of study drug up to end of study follow-up (Up to Week 32)
Felzartamab Serum Concentrations Over Time
Tidsramme: Predose and at multiple timepoints postdose up to Week 24
Predose and at multiple timepoints postdose up to Week 24
Number of Participants with Anti-drug Antibodies (ADAs) Against Felzartamab
Tidsramme: Baseline up to Week 24
Baseline up to Week 24

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Biogen

Efterforskere

  • Studieleder: Medical Director, Biogen

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

15. august 2026

Primær færdiggørelse (Anslået)

31. januar 2028

Studieafslutning (Anslået)

31. marts 2028

Datoer for studieregistrering

Først indsendt

20. juli 2026

Først indsendt, der opfyldte QC-kriterier

20. juli 2026

Først opslået (Faktiske)

23. juli 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. juli 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

20. juli 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 299GD201
  • 2026-526482-19-00 (Ctis)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Placebo

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Israel

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner